C hung Yong-ji is a South Korean billionaire whose wealth is derived from his significant, early investment in the stock market, particularly in the biopharmaceutical sector. He is not a typical industrialist or tech founder but rather a highly successful private investor. A large portion of his fortune comes from his stake in the biotech company, Alteogen.

Alteogen specializes in developing long-acting biologics and antibody-drug conjugates, a cutting-edge area of cancer therapy. As a major shareholder, Chung Yong-ji's net worth has soared along with the company's valuation, which has been driven by its promising drug development pipeline. His success highlights the immense wealth creation potential of the biotechnology industry and the rewards for savvy investors who can identify promising companies early on.